Liminatus Pharma Finalizes Highly Dilutive $4.0M Public Offering to Fund Operations

summarizeSummary

Liminatus Pharma, a nano-cap immuno-oncology company, has finalized a $4.0 million public offering of common stock and warrants, securing critical capital for operations despite significant dilution.

check_boxKey Events

• Finalized Public Offering

  Liminatus Pharma closed a $4.0 million gross public offering of 8.27 million shares, 5.543 million pre-funded warrants, and 13.813 million common stock purchase warrants.

• Dilutive Capital Raise

  The offering, with net proceeds of $3.46 million, is highly dilutive, representing over 50% of the company's market capitalization.

• Pricing Details

  Securities were offered at $0.29 per unit, a slight premium to the current stock price of $0.2735, with common warrants exercisable at $0.29.

• Placement Agent Compensation

  Maxim Group LLC received an 8.0% cash fee and warrants to purchase 690,650 shares (5.0% of shares sold) at an exercise price of $0.319.

auto_awesomeAnalysis

This 8-K details the final terms and closing of Liminatus Pharma's public offering, which was previously registered via an S-1 filing on February 11, 2026, and finalized in a 424B4 on the same day as this 8-K. The company successfully raised $4.0 million in gross proceeds, with net proceeds of approximately $3.46 million, through the sale of common stock, pre-funded warrants, and common stock purchase warrants. The offering price of $0.29 per unit (shares and warrants) is notable as it is slightly above the current market price of $0.2735, indicating some investor confidence despite the company's distressed situation. However, the offering is highly dilutive, representing over 50% of the company's current market capitalization, and includes additional warrants for the placement agent. This capital infusion is crucial for Liminatus Pharma, which recently received a Nasdaq delisting notice and settled a major legal dispute, providing necessary funds for clinical trials, research and development, and general working capital to extend its operational runway.